The British journal of dermatology最新文献

{"title":"Transient Abdominal Telangiectasia of the Newborn.","authors":"Mirain Phillips, Jenny Hughes","doi":"10.1093/bjd/ljag437","DOIUrl":"https://doi.org/10.1093/bjd/ljag437","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards Personalised Therapeutics for Epidermal Differentiation Disorders: Integrating Host Genetics, Immuno-Endotypes and the Skin Microbiome.","authors":"Thomas Sharkey, Mark Eisner, John Common, Neil Rajan","doi":"10.1093/bjd/ljag447","DOIUrl":"https://doi.org/10.1093/bjd/ljag447","url":null,"abstract":"<p><p>Epidermal differentiation disorders (EDDs), are a rare, heterogeneous grouping of monogenic disorders. EDDs, comprising the previously termed congenital ichthyosis, are characterised by epidermal barrier dysfunction, cutaneous inflammation, and associated morbidity. Immunomodulatory therapies, particularly repurposed biologics, are an emerging approach for management. However, clinical implementation has been impeded by a variable and unpredictable response rate, reflecting the genetic and immunological heterogeneity of EDD as well as raising questions over other contributory pathogenic mechanisms. Patient genotyping and immune profiling have revealed a shared immune polarisation across EDD subtypes, predominantly Th17, with some subtypes demonstrating a mixed immuno-endotype with contribution from Th2 or lL-36 mediated signalling. This improved immunological understanding has informed the repurposing of established biologics targeting IL-4R, IL-17, IL-12/23, alongside emerging interest in JAK inhibitors. Metagenomic microbiome profiling has revealed a homeostatic disruption across EDD subtypes with depleted commensal organisms, including Cutibacterium acnes and Malassezia species, and enrichment of pathobiont Staphylococcus and Corynebacterium species. Patients may be further stratified into dysbiotic groupings, with pathogenic variant and phenotypic severity influencing microbial composition. Ecological dysbiosis may contribute to immune polarisation through an \"outside-inside-outside\" model of host-microbe interactions, potentially underlying the variable response rates to repurposed biologics. In this review, we propose a \"host genome and microbiome\" framework for personalised EDD clinical management, integrating the EDD genotype and immuno-endotype (\"Host genome\"), and cutaneous microbiome as candidate simultaneous stratifiable elements. Genomic diagnosis, spurred by recent EDD reclassification, provides mechanistic context. Immuno-endotyping may enable a rational biologic selection but requires prospective validation. Microbiome profiling may guide emerging therapeutics or serve as a biomarker. We propose that a route to therapeutic restoration in EDD may require simultaneous targeting of the host-microbe axis. Delineation of the complex interplay between host genetics, immuno-endotypes, epidermal barrier dysfunction, and skin microbiome is a key priority for future research to bring this approach to the clinic.</p>","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Releasing the brake: lipid control of CD1a-autoreactive T cells in atopic dermatitis.","authors":"Tatsuya Hasegawa, Kenji Kabashima","doi":"10.1093/bjd/ljag448","DOIUrl":"https://doi.org/10.1093/bjd/ljag448","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The environmental burden of melanoma: a national stage-specific carbon footprint analysis.","authors":"Mythili Ramamurthy Srinivasan, David de Berker, Zoe C Venables, Nick J Levell, Simon Tso","doi":"10.1093/bjd/ljag440","DOIUrl":"https://doi.org/10.1093/bjd/ljag440","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Publications From Biologic or Small-molecule Trials in Psoriasis: A Methodological Systematic Review.","authors":"Huong G N Tran, Sivem Afach, Robin Guelimi, Emilie Sbidian, Laurence Le Cleach","doi":"10.1093/bjd/ljag441","DOIUrl":"https://doi.org/10.1093/bjd/ljag441","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV8-associated actinic keratosis identifies immunosuppressed patients at high risk of developing squamous cell carcinoma.","authors":"William Tuckwell, Huw J Morgan, Boris Y Shorning, Su-Yi Liew, Marcelle McDonald-Leslie, Nitya Malladi, W John Watkins, Majid Rashid, Girish K Patel","doi":"10.1093/bjd/ljag439","DOIUrl":"https://doi.org/10.1093/bjd/ljag439","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Why do Australian dermatologists screen for Strongyloides stercoralis before dupilumab?'","authors":"Timothy Chen, Heather Varcoe, Geoffrey Lee","doi":"10.1093/bjd/ljag442","DOIUrl":"https://doi.org/10.1093/bjd/ljag442","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surviving stage IV melanoma: the unfinished task of survivorship care.","authors":"Jonas A Adalsteinsson, Helga L Karadottir","doi":"10.1093/bjd/ljag438","DOIUrl":"https://doi.org/10.1093/bjd/ljag438","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.","authors":"","doi":"10.1093/bjd/ljag425","DOIUrl":"10.1093/bjd/ljag425","url":null,"abstract":"","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps in Current Chronic Spontaneous Urticaria (CSU) Management.","authors":"Angèle Soria","doi":"10.1093/bjd/ljag389","DOIUrl":"https://doi.org/10.1093/bjd/ljag389","url":null,"abstract":"<p><p>Despite advances in therapy, chronic spontaneous urticaria (CSU) remains a challenging disease with a significant impact. Although antihistamines, anti-IgE therapy and immunosuppressants form the basis of treatment, there are still substantial gaps in diagnosis, endotyping, prediction of therapeutic response and implementation of international guidelines. Newly licensed CSU therapeutic agents, such as Bruton tyrosine kinase (BTK) inhibitors and anti-interleukin-4 receptor alpha (anti-IL4Rα) agents, offer hope to patients who do not respond to treatment. However, we currently lack validated biomarkers of disease-specific features to determine which patient should receive which therapy, and the optimal positioning of these agents within the treatment sequence remains undefined. This narrative review examines the ongoing challenges in CSU management and proposes a more integrated, personalised and patient-centred approach.</p>","PeriodicalId":520789,"journal":{"name":"The British journal of dermatology","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}